6th September 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting.
6th September 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of today’s Annual General Meeting.
https://youtu.be/QJaKk3F-TQs
To view the full article click here…
5th June 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a further update regarding its US clinical and regulatory development strategy for its CTX cell therapy candidate for stroke disability.
To view the full article click here…
11th May 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has been awarded a £1.8 million grant from Innovate UK to further advance its next generation commercial cell therapy manufacturing capabilities.
To view the full article click here…
21st April 2017: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on its CTX-based cell therapy development programmes.
ReNeuron’s CTX cell therapy candidate has been featured in the BBC documentary, “Andrew Marr: My Brain and Me”, which was screened for the first time on 14 February 2017 on BBC2.